IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
出版年份 2018 全文链接
标题
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
作者
关键词
-
出版物
MODERN PATHOLOGY
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-05-25
DOI
10.1038/s41379-018-0061-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma
- (2018) Anne M. Mills et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
- (2017) David M. Gershenson et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanism of immune evasion in breast cancer
- (2017) Mozhi Wang et al. OncoTargets and Therapy
- Blocking IDO1 Helps Shrink Bladder, Cervical Tumors
- (2017) Cancer Discovery
- Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer
- (2017) Sewha Kim et al. Journal of Cancer
- Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
- (2016) Kurt A. Schalper et al. CLINICAL CANCER RESEARCH
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
- (2016) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1
- (2016) Upasana Joneja et al. JOURNAL OF CLINICAL PATHOLOGY
- The immune microenvironment of breast ductal carcinoma in situ
- (2016) Elizabeth Thompson et al. MODERN PATHOLOGY
- Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment
- (2016) Kenneth Friedman et al. MODERN PATHOLOGY
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
- (2016) David H. Munn et al. TRENDS IN IMMUNOLOGY
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- 346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors
- (2015) A. Nayak et al. EUROPEAN JOURNAL OF CANCER
- Expression of immune checkpoint molecules in endometrial carcinoma
- (2015) JIA LIU et al. Experimental and Therapeutic Medicine
- Targeting the indoleamine 2,3-dioxygenase pathway in cancer
- (2015) Yong Wha Moon et al. Journal for ImmunoTherapy of Cancer
- A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
- (2015) Hatem H. Soliman et al. Oncotarget
- Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
- (2014) H. R. Ali et al. ANNALS OF ONCOLOGY
- The Targeting of Indoleamine 2,3 Dioxygenase -Mediated Immune Escape in Cancer
- (2014) Trine Zeeberg Iversen et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy
- (2014) Kim A Reiss et al. Immunotherapy
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis
- (2014) M. T. Isla Larrain et al. TUMOR BIOLOGY
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Immune checkpoints
- (2014) Akhil Chawla et al. OncoImmunology
- Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1
- (2013) Jörg B. Engel et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry
- (2013) Hatem Soliman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Indoleamine 2,3 dioxygenase and metabolic control of immune responses
- (2012) David H. Munn et al. TRENDS IN IMMUNOLOGY
- B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
- (2010) J.-J. Park et al. BLOOD
- IDO Upregulates Regulatory T Cells via Tryptophan Catabolite and Suppresses Encephalitogenic T Cell Responses in Experimental Autoimmune Encephalomyelitis
- (2010) Y. Yan et al. JOURNAL OF IMMUNOLOGY
- Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer
- (2009) Aaron S Mansfield et al. BMC CANCER
- IDO Mediates TLR9-Driven Protection from Experimental Autoimmune Diabetes
- (2009) F. Fallarino et al. JOURNAL OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now